hydroxyurea has been researched along with Brain Vascular Disorders in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sickle cell disease is a common and life-threatening haematological disorder that affects millions of people worldwide." | 2.55 | Sickle cell disease. ( Abboud, MR; de Montalembert, M; Tshilolo, L; Ware, RE, 2017) |
| "Hydroxyurea has proven efficacy in numerous clinical trials as a disease-modifying treatment for patients with sickle cell anemia (SCA) but is currently under-used in clinical practice." | 1.42 | Optimizing hydroxyurea therapy for sickle cell anemia. ( Ware, RE, 2015) |
| "Stroke is a common cause of morbidity and mortality in sickle cell disease (SCD) and silent cerebral infarction is the most common form of neurologic injury." | 1.39 | Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians. ( Calvaruso, G; Iannello, S; Maggio, A; Pecoraro, A; Rigano, P; Steinberg, MH, 2013) |
| "Hydroxyurea can increase fetal hemoglobin (HbF) and improve the clinical course of sickle cell disease (SCD) patients." | 1.29 | A cautionary note regarding hydroxyurea in sickle cell disease. ( Lubin, BH; Vichinsky, EP, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Bernaudin, F | 1 |
| Rankine-Mullings, A | 1 |
| Reid, M | 1 |
| Soares, D | 1 |
| Taylor-Bryan, C | 1 |
| Wisdom-Phipps, M | 1 |
| Aldred, K | 1 |
| Latham, T | 1 |
| Schultz, WH | 1 |
| Knight-Madden, J | 1 |
| Badaloo, A | 1 |
| Lane, A | 1 |
| Adams, RJ | 1 |
| Ware, RE | 4 |
| Ansari, J | 1 |
| Moufarrej, YE | 1 |
| Pawlinski, R | 1 |
| Gavins, FNE | 1 |
| Rigano, P | 1 |
| Pecoraro, A | 1 |
| Calvaruso, G | 1 |
| Steinberg, MH | 2 |
| Iannello, S | 1 |
| Maggio, A | 1 |
| de Montalembert, M | 2 |
| Tshilolo, L | 1 |
| Abboud, MR | 1 |
| Brousse, V | 1 |
| Gandhi, S | 1 |
| Height, S | 1 |
| Dick, MC | 1 |
| O'Driscoll, S | 1 |
| Abihsera, G | 1 |
| Rees, DC | 1 |
| Vichinsky, EP | 1 |
| Lubin, BH | 1 |
| Kinney, TR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of the Use of Oral Ketamine for Treatment of Vaso-Occlusive Pain in Adolescents and Young Adults[NCT05378555] | Phase 3 | 10 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| Prospective Clinical Study on Early Inflammatory, Cell Adhesion and Hemostatic Plasmatic Markers of Endothelial Dysfunction in Children With Sickle Cell Disease (SCD)[NCT04839159] | 41 participants (Anticipated) | Interventional | 2012-05-10 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for hydroxyurea and Brain Vascular Disorders
| Article | Year |
|---|---|
What is the place of hematopoietic stem cell transplantation in the management of cerebral vasculopathy in children with sickle cell anemia?
Topics: Allografts; Anemia, Sickle Cell; Cerebrovascular Disorders; Child; Hematopoietic Stem Cell Transplan | 2020 |
Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Communication; Cerebrovascular Disorders; Disease Pro | 2018 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
1 trial available for hydroxyurea and Brain Vascular Disorders
| Article | Year |
|---|---|
Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Cerebrovascular Circulati | 2021 |
5 other studies available for hydroxyurea and Brain Vascular Disorders
| Article | Year |
|---|---|
Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Topics: Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Cerebral Infarction; Cerebr | 2013 |
Optimizing hydroxyurea therapy for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Drug Adminis | 2015 |
Combined blood transfusion and hydroxycarbamide in children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Brain Ischemia; Cerebral Infarction; Cerebral Re | 2013 |
A cautionary note regarding hydroxyurea in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Blood Transfusion; Cerebral Hemorrhage; Cerebrovascular Disorders; Femal | 1994 |
Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Blood Group Incompatibility; Blood Transfusion; Cerebrovascular Disorder | 1995 |